Evidence map›Paper›PMID 30619296›Full record

ReviewFrontiers in immunology2018

Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations.

Silvia Sánchez-Ramón, Laura Conejero, Mihai G Netea, David Sancho, Óscar Palomares, José Luis Subiza

3 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 151 papers.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03305341 early_phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation

Conducting an Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients With Controlled Cancers.

TypeinterventionalSponsorHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairRan2025 to 2026Enrolled20ConditionsCovid19ArmsCOVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
NCT04363814 phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19

TypeinterventionalSponsorInmunotek S.L.Ran2020 to 2022Enrolled100ConditionsCOVID-19ArmsBactek-R
NCT05208060 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

A Phase I/II Randomized, Prospective, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

TypeinterventionalSponsorInmunotek S.L.Ran2023 to 2025Enrolled48ConditionsImmune ResponseArmsMV130, Placebo
3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 250 citations in OpenAlex.

  1. Trial
  2. Trained Immunity in Childhood Vaccination.Acta paediatrica (Oslo, Norway : 1992) · 2026
    Review
  3. Review
  4. Editorial comment: Efficacy and safety of bacterial immunostimulants in immunodeficient individuals: A systematic review and meta-analysis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Heat-killedFrontiers in immunology · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Maladaptive trained immunity in viral infections.The Journal of clinical investigation · 2025
    Review

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Silvia Sánchez-RamónDepartment of Clinical Immunology and IdISSC, Hospital Clínico San Carlos, Madrid, Spain.
Laura ConejeroInmunotek, Alcalá de Henares, Spain.
Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
David SanchoImmunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
Óscar PalomaresDepartment of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.
José Luis SubizaInmunotek, Alcalá de Henares, Spain.
Inmunotek (Spain) · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESRadboud University Medical Center · NLSpanish National Centre for Cardiovascular Research · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Challenge with specific microbial stimuli induces long lasting epigenetic changes in innate immune cells that result in their enhanced response to a second challenge by the same or unrelated microbial insult, a process referred to as trained immunity. This opens a new avenue in vaccinology to develop

Indexed as

Immunologic MemoryAdaptive ImmunityAdjuvants, ImmunologicHumansImmunity, InnateImmunogenicity, VaccineInfection ControlInfectionsReceptors, Pattern RecognitionVaccinesAdjuvants, ImmunologicReceptors, Pattern RecognitionVaccinesadjuvantsimmunostimulantsinnate immunitypattern recognition receptors (PRRs)PRR-ligandstrained immunitytrained immunity-based vaccines (TIbV)vaccines

Identifiers

PMID30619296
PMCPMC6304371
OpenAlexW2905235893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.